Through ongoing collaboration, new companion diagnostic aims to deliver next-generation sequencing results in as little as 24 hours to help advance precision oncology.

Nested Therapeutics, a precision oncology company targeting previously undruggable cancer targets, closed on a $90 million Series A financing, bringing total financing to $125 million since its inception in 2021.